Factor Therapeutics

Our sincere thanks to all our shareholders, partners and the patients who participated in the study - while not the outcome we hoped for, the wider field of wound care research will benefit from the VF00102 study

Our Phase 2 results announced this morning showed that VF001 was unable to improve on standard care for healing VLUs. More information at factor-therapeutics.com/investors/asx-…

Factor Therapeutics has appointed a transaction advisor - see the full announcement at factor-therapeutics.com/investors/asx-…

Treatment is finished in our Phase 2 VLU trial! Readout is now only a few weeks away asx.com.au/asxpdf/2018100… #researchmatters #woundcare #phase2

Shareholder Update Q3 2018 bit.ly/2yfB4fh

An update on our pipeline was released today - progress in our other clinical and early research programmes. asx.com.au/asxpdf/2018100…

CEO Ros Wilson is speaking this afternoon in Adelaide at Broker Meets Biotech #ClinicalResearch #woundcare #researchmatters #phase2

...and here’s the video of the interview with @ScottPowerSays Factor Therapeutics (ASX: FTT): Dr Rosalind Wilson, Chief Executive Officer youtu.be/p3LP2SR0c6k via @YouTube

Ros recently sat down with Scott Power of Morgans to give an update on our countdown towards readout. ‘Under the microscope: Dr Rosalind Wilson, CEO of Factor Therapeutics (ASX: FTT)’ on #SoundCloud #np soundcloud.com/morgans-financ…

Our CEO, Ros Wilson, is about to present and update at Broker Meets Biotech in Perth. View the presentation here asx.com.au/asxpdf/2018081…

Presenting Factor at Bioshares as we approach readout - exciting times ahead! #bioshares #woundcare #clinicaltrials #researchmatters

Just released a report on Factor Therapeutics $FTT. Looks highly undervalued. NPV = 33.5 cents/share (fully diluted) prior to phase IIb readout in Q4 CY18. NPV = 52 cents after, if +ve. Multiple catalysts to get it there. It’s a good one! @biotech_daily @asxlongtail @Factor_Tx

A big thank you to everyone who helped ensure the successful recruitment of our Phase 2 clinical trial. We look forward to sharing the results with you. #ResearchMatters

Our CEO is sleeping outside tonight as part of the 2018 Vinnies CEO Sleepout #vinniesQLD #CEOSleepoutAU

Here’s our latest trial update - May was outstanding and we’re looking forward to delivering results later this year asx.com.au/asxpdf/2018061…

Many thanks for those who came along to today’s AGM. Our Chairman’s address and CEO Report are available now asx.com.au/asxpdf/2018052…

Factor’s CEO, Ros Wilson, is taking part in the Vinnies CEO Sleepout to raise funds for people experiencing homelessness. Please support her and help fellow Australians in need. ceosleepout.org.au/s/8569/45072/t

Congratulations to Derek Van Lonkhuyzen on a great presentation this afternoon, sharing some of our preclinical data and highlighting the Phase 2 clinical programme

Our quarterly trial update was released this week - the study is 70% recruited as we continue to progress toward this key milestone asx.com.au/asxpdf/2018041…